115 IL-6 inhibitors in hospitalised COVID-19 patients 5 Group Estimate (95% CI) 8 mg/kg 1 Fixed dose tocilizumab -0.72 (-1.80 to 0.36) Low dose tocilizumab -3.16 (-4.37 to -1.95) Sarilumab 400mg -2.85 (-3.92 to -1.79) Supplementary Table 10. Multivariable linear regression analysis, differences in hospital LOS between different treatment groups, corrected for age, sex, immunocompromised status and Charlson Comorbidity index. For patients with 2 COVID-19 hospital admissions with <90 days in between, 75% were randomly selected and their hospital LOS consisted of the first admission only Group Estimate (95% CI) 8 mg/kg 1 Fixed dose tocilizumab -0.42 (-1.82 to 0.98) Low dose tocilizumab -1.81 (-3.55 to -0.08) Sarilumab 400mg -0.98 (-2.43 to 0.46) Supplementary Table 11. Multivariable linear regression analysis, differences in ICU LOS between different treatment groups, corrected for age, sex, immunocompromised status and Charlson Comorbidity index Group Estimate (95% CI) 8 mg/kg 1 Fixed dose tocilizumab -0.50 (-2.19 to 1.19) Low dose tocilizumab -0.26 (-2.42 to 1.89) Sarilumab 400mg 0.30 (-1.49 to 2.09) Supplementary Table 12. Multivariable linear regression analysis in patients who survived, differences in ICU LOS, corrected for age, sex, immunocompromised status and Charlson Comorbidity index Group Hazard ratio (95% CI) 8 mg/kg 1 Fixed dose tocilizumab -1.07 (-2.67 to 0.53) Low dose tocilizumab -1.53 (-3.54 to 0.48) Sarilumab 400mg -0.78 (-2.46 to 0.91) Supplementary Table 13. Multivariable linear regression analysis in patients with a complete LOS, differences in ICU LOS between the four different treatment groups, corrected for age, sex, immunocompromised status and Charlson Comorbidity index
RkJQdWJsaXNoZXIy MTk4NDMw